Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.
about
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.Dendritic cell vaccination in melanoma patients: From promising results to future perspectivesImmune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells.Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.miR-128 enhances dendritic cell-mediated anti-tumor immunity via targeting of p38.Optimal extent of completion lymphadenectomy for patients with melanoma and a positive sentinel node in the groin.Trial watch: Dendritic cell-based anticancer immunotherapy.Trial watch: Immunogenic cell death induction by anticancer chemotherapeuticsDendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right TimeNext Generation Cancer Vaccines-Make It Personal!
P2860
Q27323878-D7D17D50-D78C-41D4-8949-CCE15E2AFA67Q30846001-97901EED-44D2-44BF-BFD9-A689CB52BE78Q36992766-357E9FAC-4AD2-4BB3-BFBB-5A5917885B44Q37222157-04D70A6B-D26C-4E3B-95B4-495465DC4F8DQ37224609-ABBAEA6D-24A9-4937-93F4-7F23DD60251BQ37741161-CB820B27-C92A-4498-AF20-E2AFFA768D2EQ38850950-597BFAD3-5159-4EAE-813C-E299CD2659DBQ39079690-04C612E3-4350-47D8-85D1-87F6D2C6CB56Q39243064-61AA8C0B-DD85-41D5-989A-01FA0551E765Q42835949-16298033-EBC1-4236-AD32-C35FC2852CB0Q47669815-8FF5BC09-F6F9-4469-B90B-75C618F680B2Q53109846-BD98BAB6-C997-488B-B767-2AEFAAB4C0D5Q56594845-B211D158-44EB-4C85-8F49-95849E22D1FFQ57486475-18BE09FB-78E8-4F83-865F-DACBDE04604AQ58791982-D1EC29C6-ECD6-4021-A43A-168F94571276
P2860
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Favorable overall survival in ...... nt dendritic cell vaccination.
@ast
Favorable overall survival in ...... nt dendritic cell vaccination.
@en
type
label
Favorable overall survival in ...... nt dendritic cell vaccination.
@ast
Favorable overall survival in ...... nt dendritic cell vaccination.
@en
prefLabel
Favorable overall survival in ...... nt dendritic cell vaccination.
@ast
Favorable overall survival in ...... nt dendritic cell vaccination.
@en
P2093
P2860
P50
P1433
P1476
Favorable overall survival in ...... ant dendritic cell vaccination
@en
P2093
Carl G Figdor
Cornelis J A Punt
Cornelis Verhoef
Dirk J Grunhagen
Erik H J G Aarntzen
Florentien E M In 't Hout
Gerty Schreibelt
Jeroen H A Creemers
Johannes H W de Wilt
Johannes J Bonenkamp
P2860
P304
P356
10.1080/2162402X.2015.1057673
P577
2015-06-05T00:00:00Z